The oral c-Met inhibitor tivantinib missed its primary endpoint of improving overall survival vs. placebo in a phase III hepatocellular carcinoma (HCC) study, calling into question the future of the program, licensed by Arqule Inc. to Daiichi Sankyo Group in December 2008, even as another phase III study of the candidate in Japan progresses. Shares in Arqule (NASDAQ:ARQL) fell 18.4 percent, closing at $1.20 on Friday.